Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-04-04

Clinical Trial Update: Lucentis KAV Study [Phase 3]

View source ↗

Summary

An update on a Phase 3 clinical trial of Lucentis (ranibizumab) for age-related macular degeneration. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lucentis (ranibizumab)

Snippet

Sponsor: The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery | Conditions: Age Related Macular Degeneration | Phase 3 | Status: COMPLETED